Anemia treatment with Recombinant Human Erythropoietin in patients with Chronic Kidney Disease, pre-dialysis phase.

Center for Genetic Engineering and Biotechnology (CIGB)0 个研究点目标入组 20 人开始时间: 2010年12月20日最近更新: 2024年8月19日

适应症

试验速览

暂无简介。

研究类型: Interventional
分配方式: Non-randomized controlled trial. Masking: Open. Control group: Uncontrolled. Assignment: Single group. Purpose: Treatment

•Glomerular Filtering Index (GFI): 59-30mL/min. Anemia under the following criteria: moderate anemia occurs with hemoglobin (Hb) concentration = 10.5 and 11.5 g/dL, and hematocrit (Ht) % = 30 and 33, in women and men, respectively. Patient’s consent in writing. Patients over 18 years of age.

•Previous treatment on recombinant human erythropoietin. Patients on ERC under dialysis. Pregnancy, puerperium or breastfeeding. Septic syndrome. Iron deficiency (serum iron lower than 60 mcg/dL). Active oncological disease or patients on chemotherapy. Patients on hormonal preparations (except thyroid hormone, contraceptives, and insulin). Liver condition caused by TGP and TGO values doubling normal values. Uncontrolled high blood pressure (diastolic pressure equal to or higher than 90 and/or systolic pressure equal to or higher than 150 mmHg). Severe psychiatric disorder, mental retardation or any other condition preventing the patient from giving his/her consent. Folic acid or vitamin B12 deficiency (suspicious megaloblastic anemia by hematic biometry). Thrombocytosis (equal to or higher than 600,000/mm3). Active bleeding at any level. Aplastic anemia. Autoimmune disease. Hemoglobinopathies and membranopathies. Active collagen disease.

发起方

Center for Genetic Engineering and Biotechnology (CIGB)